Biblio Discovery — Demo Discovery Service

48 results for "Francesco Perrone"

Showing 1–20 · 0.37 seconds · RSS

  1. Journal Article

    FINANCIAL TOXICITY: AN EMERGING PROBLEM FOR CANCER PATIENTS

    Francesco Perrone

    Journal of Cancer Rehabilitation, Vol. 7 No. 4 · 2024 · English · DOAJ Scopus

    Financial toxicity is one of the emerging problems in the management of cancer patients, mainly in countries characterized by a private health system and in those defned as low-middle income countries (LMIC). However, data published in 2016 have shown that it is also a problem in Italy.

  2. Journal Article

    Planning and allocating resources for pharmaceuticals to health care organisations: a proposal from the Regional Pharmaceutical Policies Forum

    Claudio Jommi; Barbara Rebesco; Francesco Perrone et al.

    Global & Regional Health Technology Assessment, Vol. 12 No. 1 · 2025 · Italian · DOAJ Scopus

    Introduction: This document illustrates the results of a multi-disciplinary and multi-stakeholder Working Group (WG), focused on planning and allocation of resources for pharmaceuticals from the Regions to the Health Authorities. The WG was carried out during the Fourth Edition of the Regional…

  3. Journal Article

    A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan

    Paolo Chiodini; Laura Arenare; Maria Carmela Piccirillo et al.

    Contemporary Clinical Trials Communications, Vol. 20 · 2020 · English · DOAJ Scopus

    Background: Tocilizumab, an IL-6 receptor antagonist, was suggested as a possible treatment of severe or critical COVID-19 pneumonia in a small Chinese study. The TOCIVID-19 trial evaluates efficacy and tolerability of tocilizumab in the treatment of patients with severe or critical COVID-19…

  4. Journal Article Full text

    Master Protocols for Precision Medicine in Oncology: Overcoming Methodology of Randomized Clinical Trials

    Raimondo Di Liello; Maria Carmela Piccirillo; Laura Arenare et al.

    Life, Vol. 11 No. 11 · 2021 · English · DOAJ Scopus

    Randomized clinical trials are considered the milestones of clinical research in oncology, and guided the development and approval of new compounds so far. In the last few years, however, molecular and genomic profiling led to a change of paradigm in therapeutic algorithms of many cancer types…

  5. Journal Article Full text

    The Other Side of the Same Coin: Beyond the Coding Region in Amyotrophic Lateral Sclerosis

    Paola Ruffo; Benedetta Perrone; Francesco Perrone et al.

    Pharmaceuticals, Vol. 18 No. 10 · 2025 · English · DOAJ Scopus

    Transposable elements (TEs), once regarded as genomic “junk,” are now recognized as powerful regulators of gene expression, genome stability, and innate immunity. In the context of neurodegeneration, particularly Amyotrophic Lateral Sclerosis (ALS), accumulating evidence implicates TEs as active…

  6. Journal Article

    The opportunity of patient-journey studies for academic clinical research in oncology

    Raimondo Di Liello; Ciro Gallo; Francesco Perrone et al.

    BMJ Open, Vol. 11 No. 9 · 2021 · English · DOAJ Scopus

    A wave of new treatments and treatment combinations are becoming available for solid tumours. Trials performed to obtain registration establish a positive benefit-risk but unavoidably leave many questions unanswered on place-in-therapy and the relative efficacy of different treatment sequences…

  7. Journal Article Full text

    Selective Silencing of TDP-43 P. G376D Mutation Reverses Key Amyotrophic Lateral Sclerosis-Related Cellular Deficits

    Roberta Romano; Giorgia Ruotolo; Francesco Perrone et al.

    Biomolecules, Vol. 16 No. 3 · 2026 · English · DOAJ Scopus

    Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease for which there is currently no cure. Dominant mutations in the TARDBP gene are causative of ALS. In particular, the p. G376D substitution in TDP-43 causes familial ALS and it is associated with TDP-43 mislocalization in the…

  8. Journal Article

    Designing, producing and exemplifying videos to support reflection and metacognition for in-service teachers training

    Valentina Toci; Loredana Camizzi; Serena Goracci et al.

    Je-LKS: Journal of E-Learning and Knowledge Society, Vol. 11 No. 2 · 2015 · English · DOAJ Scopus

    In this paper we document a six-phase video production process designed to support teachers’ continuous professional development in three disciplinary areas: scientific, linguistic-literary and foreign languages areas. This production has been carried out within the NOP1 - National Operational…

  9. Journal Article Full text

    Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis

    Bruno Vincenzi; Massimo Di Maio; Marianna Silletta et al.

    PLOS ONE, Vol. 10 No. 7 · 2015 · English · PLOS Scopus

    Background: The European Association for the Study of the Liver (EASL) criteria and the modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to evaluate radiological response in patients affected by HCC and treated with loco-regional procedures. Several studies…

    Also available at: DOAJ

  10. Journal Article

    The Standard of Care Definitions on COVID-19 Pharmacological Clinical Trials: A Systematic Review

    Antonio Addis; Laura Amato; Fabio Cruciani et al.

    Frontiers in Pharmacology, Vol. 12 · 2021 · English · DOAJ Scopus

    Background: Standard of Care (SoC) has been used with different significance across Randomized Clinical Trials (RCTs) on the treatment of Covid-19. In the context of a living systematic review on pharmacological interventions for COVID-19, we assessed the characteristics of the SoC adopted in the…

  11. Journal Article

    Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy

    Bishal Gyawali; Francesco Barone-Adesi; Francesco Perrone et al.

    BMJ Open, Vol. 9 No. 12 · 2019 · English · DOAJ Scopus

    Objective To investigate whether the prices of new anticancer drugs correlated with their relative benefit despite negotiation.Design Retrospective cross-sectional study correlating new anticancer drugs prices with clinical outcomes.Setting We did a retrospective cross-sectional study including all…

  12. Journal Article

    The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018

    Paolo A. Ascierto; Paolo Bruzzi; Alexander Eggermont et al.

    Journal of Translational Medicine, Vol. 17 No. 1 · 2019 · English · DOAJ Scopus

    Abstract The great debate session at the 2018 Melanoma Bridge congress (November 29–December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether…

  13. Journal Article

    The “Great Debate” at Immunotherapy Bridge 2020, December 3rd, 2020

    Paolo A. Ascierto; Joshua Brody; Lisa H. Butterfield et al.

    Journal of Translational Medicine, Vol. 19 No. 1 · 2021 · English · DOAJ Scopus

    Abstract As part of the 2020 Immunotherapy Bridge virtual congress (December 2nd–3rd, Italy), the Great Debate session featured counterpoint views from leading experts on three clinical questions in immunotherapy today. The first of these was whether antitumoral vaccination is still a treatment…

  14. Journal Article

    Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy

    Ernesta Cavalcanti; Vittoria Barchiesi; Dionigio Cerasuolo et al.

    Analytical Cellular Pathology, Vol. 2016 · 2016 · English · DOAJ Scopus

    Objectives. Serum cystatin C seems to be an accurate marker of glomerular filtration rate (GFR) compared to serum creatinine. The aim of this work was to explore the possibility of using serum cystatin C instead of serum creatinine to early predict renal failure in cancer patients who received…

  15. Journal Article Full text

    The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline

    Massimo Di Maïo; Ethan Basch; Fabrice Denis et al.

    Annals of Oncology · 2022 · English · OpenAlex Scopus

    Patients with cancer frequently experience symptoms related to their disease or treatment-related toxicities. Symptom management through optimal supportive care is a foundation of quality care. While objective toxicities and laboratory results are amenable to reporting by health care personnel…

  16. Journal Article Full text

    Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology

    Giacomo Pascarella; Arturo Capasso; Antonio Nardone et al.

    PLOS ONE, Vol. 14 No. 1 · 2019 · English · PLOS Scopus

    Aim: The aim of the present study was to assess the estimated “per patient” total cost for a single Oncologic Italian Cancer Center participating in a multicenter clinical trial with new anticancer biological agents using the activity-based costing (ABC) methodology. Methodology: Nine randomized…

  17. Journal Article

    Comparison of baseline patient characteristics in phase 1 and phase 2/3 clinical trials for anticancer treatments

    Maria Lucia Iacovino; Simone Talucci; Laura Arenare et al.

    Journal of Translational Medicine, Vol. 23 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Background Characteristics of patients significantly differ between registrational clinical trials (CTs) and Italian real-world practice, with older median age, higher elderly (≥ 65) rate and worse performance status (PS) in the latter, without imbalance in female rate. We compared the…

  18. Journal Article Full text

    Time Spent for Activation of Non-Profit Studies in Oncology in Italy

    Gianfranco De Feo; Simona Signoriello; Jane C. Bryce et al.

    PLoS ONE, Vol. 5 No. 7 · 2010 · English · PLOS Scopus

    Aim: The aim of this paper is to describe the time spent to activate oncological non-profit clinical trials promoted in Italy by the National Cancer Institute of Naples, following the implementation of recent European laws. Methodology: Data about the process of activation of 5 non-profit…